Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1283-1292.

• Liver Failure • Previous Articles     Next Articles

Clinical application research of non-biological artificial liver therapy primarily utilizing the DPMAS mode in treating pre-and early liver failure

Zhao Tingting1,2, Zhang Fenna1, Lv Beibei1, Song Yujuan1, He Na1   

  1. 1. The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077,China;
    2. Xi'an Medical University,Xi'an 710021, China
  • Received:2025-09-14 Online:2026-09-30 Published:2026-11-16
  • Contact: He Na, Email: ylhena@163.com

Abstract: Objective This study aimed to explore the clinical application value of non-biological artificial liver therapy primarily utilizing the double plasma molecular adsorption system (DPMAS) in treating pre- and early-stage liver failure. Methods Clinical materials of 170 patients, who were diagnosed with liver failure at the department of hepatology at the First Affiliated Hospital of Xi'an Medical University and Xi'an International Medical Center, as well as the Department of Hepatology at Yulin Traditional Chinese Medicine Hospital, were retrospectively collected and divided into DPMAS group (120 cases received medical treatment combined DPMAS, including 50 in pre- and early-stage, 50 in middle stage, and 20 in the end stage) and control group (50 cases received medical treatment) according to their treatment. Then, the feasibility and clinical benefit degree of DPMAS were analyzed according to the indices of liver and kidney function, coagulation function, inflammatory levels, extrahepatic complications, and survival rates of patients between different groups and different stages. Results Compared with the control group, the DPMAS group could significantly ameliorate the indices of liver and kidney and coagulation function, including alanine aminotransferase [(70.32±29.40) vs. (146.94±46.53)](U/L), aspartate aminotransferase [(59.20±21.63) vs. (122.27±41.84)](U/L), total bilirubin [(98.37±36.95) vs. (135.03±41.04)](μmol/L), creatinine [(61.30±12.82) vs. (66.80±7.82)](μmol/L), international normalized ratio [(1.40±0.06) vs. (1.56±0.29)] and prothrombin activity [(70.3%±13.82%) vs. (60.21%±15.00%)](all P<0.05), reduce the inflammatory associated C-reactive protein [(11.72±1.94) vs. (15.69±2.10)](mg/L), tumor necrosis factor [(22.53±6.50) vs. (42.85±16.85)](mg/L), and interleukin-6 [(16.88±2.03) vs. (30.69±5.59)](ng/L) (all P<0.001), and hepatic encephalopathy incidence (0% vs. 2%, P=0.016), and improve the 12-week and 24-week survival rates (90% vs. 80%, 88% vs. 76%, P=0.048, 0.030) of patients with the pre-and early-stage liver failure. In the comparison of different stages, the improvement degrees of liver and kidney functions, coagulation and inflammatory indicators of patients in the pre- and early-stage after DPMAS treatment were significantly better than those in the middle and late stages (P<0.001), the incidence of extrahepatic complications was lower (P<0.001), and the 24-week survival rate was significantly higher than that in the middle stage and the late stage (88% vs. 60% vs. 20%, P<0.001). Conclusion Pre- and early-stage liver failure represents a priority time for the non-biological artificial liver mainly based on DPMAS in treating liver failure. It can effectively improve the liver and kidney functions, coagulation and inflammatory status of patients, reduce the risk of complications and increase the long-term survival rate.

Key words: Pre-and early stages, Liver failure, DPMAS, Non-bioartificial liver, Prognosis